A health impact assessment of increased aspirin use in Wales.
OBJECTIVE
To estimate the likely magnitude of health impact if all individuals at increased risk of cardiovascular events in Wales (total population 2.9 million) took low-dose aspirin.


METHODS
Data from a variety of different sources were collected and systematically combined using simple methods and conservative assumptions.


RESULTS
Aspirin may reduce cardiovascular mortality by 2-25% and avoid 330-3250 deaths per annum after allowing for a small number of fatal undesirable effects.


CONCLUSIONS
Wales might lead the way in developing an aspirin programme.
Morgan
G
G
Welsh Aspirin Group Secretary, 41 Ffordd Beck, Gowerton, Swansea, Wales SA4 3GE, UK. morgan@ffordbeck.fsnet.co.uk
D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors; D014852:Wales / Q000453:epidemiology
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin